Diabetic patients in poor glycemic control show increased glycation of total plasma proteins, but little is yet known about the relative extents to which the various individual proteins are glycated. Thus, we studied the non-enzymic glycation of several major plasma proteins and plasma protein fractions in normal and diabetic patients. In vivo glycation for most plasma proteins was very low in non-diabetic patients, only gamma globulin showing more than 5% glycation. In diabetic plasmas, glycation was much greater, immunoglobulins again showing the greatest proportion, followed in descending order by albumin, complement C3, fibrinogen, transfernn, haptoglobin, and alpha-i -antitrypsin. When plasma proteins were glycated in vitro, this order was lgG > complement C3 > albumin > transferrin > haptoglobin > alpha-i-antitrypsin. In general, proteins with the longest biological half-lives, such as lgG and albumin, showed the greatest in vivo glycation. On the other hand, proteins with high intrinsic glycability, such as complement C3, showed moderate glycation, despite a short half-life. Except for albumin, more-basic proteins showed greater glycation than acidic proteins, but there was poor correlation between mole percent lysine and glycation. Evidently the relative extents of glycation of different plasma proteins are a complex function of integrated glucose concentrations over time and of the half-life and chemical characteristics of each protein.
radioactivity.
Increasing amounts of glycated serum, from 25 pL to 1 mL, were applied to Glycogel B (Pierce Chemical Co., Rockford, IL 61105); the analytical recovery of bound protein was measured with Coomassie Blue (Bio-Rad, Richmond, CA 94804) and the recovery of radiolabeled glycated protein was measured in a Packard scintillation counter. Bound fractions were also electrophoresed as described below and the recovery of labeled glucose was measured for each major protein fraction.
Separation of glycated and non-glycated proteins.
We diluted 375 L of serum or plasma to 750 pL with Pierce Equilibration-Wash Buffer and applied to 1.5-mL Glycogel B affinity columns, which were regenerated four times immediately before use. The columns were washed twice with 5-mL portions of Equilibration-Wash Buffer (Pierce). The pass-through and wash fractions were combined as the "unbound" (non-glycated) fraction. The "bound" (glycated) fraction was eluted with Elution Buffer (Pierce). Glycated and non-glycated protein fractions were lyophilized, redissolved in phosphate-buffered isotonic saline (pH 7.4) and dialyzed against the same buffer. Sample volumes were adjusted with saline to bring the protein concentrations to those present in the original serum or plasma specimens.
Agarose gel electrophoresis
of serum proteins. Aliquots (4 pL) of glycated or non-glycated serum proteins were applied to commercially prepared agarose gels (Panagel; Princeton Separations, Inc., Freehold, NJ 07728) and electrophoresed in an LKB 2117 Multiphore horizontal electrophoresis apparatus (LKB, Bromma, Sweden). Electrophoresis was for 1 h at 10#{176}C at pH 8.6 according to the Panagel protocol. Relative densities of individual proteins were determined with an LKB 2202 Ultroscan Laser Densitometer equipped with an LKB 2220 recording integrator. Linearity was validated against a neutral-density standard (Helena Laboratories, Beaumont, TX 77704). Total protein was measured by a modified biuret method in a DACOS analyzer (Coulter Electronics, Inc., Hialeah, FL 33010).
Specific protein assays. Concentrations of IgG, complement C3, haptoglobin, alpha-1-antitrypsin, and transferrin in the glycated and non-glycated serum or plasma fractions were determined by immunoturbidimetry, with use of SPQTM test kits (Atlantic Antibodies, Scarborough, ME 07040) and a Cobas-Bio centrifugal analyzer (Roche Diagnostic Systems, Nutley, NJ 07110). Samples containing glycated and non-glycated proteins were diluted appropriately with phosphate-buffered isotonic saline and assayed according to kit protocols. Albumin concentrations in fractionated specimens were determined with bromcresol green at 630 nni in a Cobas-Bio analyzer. Fibrinogen concentrations were determined in a Fibrometer Precision Coagulation Timer (BBL Microbiology Systems, Cockeysville, MD 21030) with kit reagents from American Dade (Aguada, PR 00602). Hemoglobin A1 was measured at the Soret peak (415 nm) after separation on Glycogel affinity columns.
Results
The data in Figure 1 
Diabetics with increased
hemoglobin A1 showed much greater glycation of serum proteins than did normal individuals, and there were notable differences in the extent to which different classes of proteins were glycated. Alpha-i and alpha-2 globulins showed little glycation, even in those patients with extremely increased hemoglobin A1. In contrast, gamma globulins were glycated by as much as 50% in several patients. Albumin and beta globulins also showed striking increases in glycation, especially in patients with the greater increases of hemoglobin A1. Among the beta globulins, transferrin appeared to remain mostly non-glycated, whereas complement C3 showed substantial glycation. To obtain more quantitative information about the glycation of certain proteins of clinical interest, we used immunoturbidimetric and other appropriate assays (indicated above) on fractionated plasmas from an additional group of normal individuals and diabetic patients (Figure 3) . Euglycemic, non-diabetic individuals showed much lower glycation of all proteins examined than did the diabetics. However, there were reproducible, substantial differences in the extent to which these proteins were glycated in both diabetic and normal individuals. linmunoglobulin G showed the greatest glycation, alpha-1-antitrypsin and haptoglobin the least. Albumin showed the most marked increase in glycation in diabetics as compared with normals. There is an apparent discrepancy in the data between Figure 3 and Table 1 , relative to albumin and, more notably, iminunoglobulins. Some of the disparity may be a reflection of the specific nature of the iminunoassays as opposed to the generic nature of electrophoresis.
Also, both fractions show extensive glycation, so densitometric scanning may overestimate these fractions.
To determine if quantitative differences in glycation of individual proteins were attributable to differences in their intrinsic susceptibilities to non-enzymic glycation, serum specimens from euglycemic individuals were incubated at 25#{176}C in the presence of 0.5 mol of glucose per liter (final concentration) for periods of two to 10 days, after which the glycated and non-glycated proteins were separated on Glycogel. Individual columns were loaded with 25,50, 100,400, or 800 ML of this treated serum. The percent glycation of the major serum fractions was determined. Representative agarose gel proffles and glycation curves derived from laser scans of them are shown in Figures 4 and 5. There were no observable differences in the patterns or recoveries obtained relative to the amount of protein applied to the columns. All classes of proteins showed at least 60% glycation after 10 days of incubation. Fibrinogen and gamma globulins showed the highest proportions of glycation, about 80% and 60%, respectively, after only two days of incubation. In contrast, the alpha-i and alpha-2 globulins were glycated at less than half that rate. Albumin and beta globulins showed intermediate rates of glycation. Figure 6 illustrates the time course of in vitro glycation for specific proteins, based on immunoturbidimetric data.
Immunoglobulin G was most rapidly glycated, followed by complement C3. On the other hand, alpha-1-antitrypsin and haptoglobin were glycated at the slowest rates among the Symbolsas in Figure 2 substantial glycation after a sufficient interval of incubation in 0.5 mol/L glucose.
Discussion
The ability of boronic acid affinity columns to separate glycated proteins from non-glycated proteins is well established (11) and is the basis for their use in assays of glycated hemoglobin, albumin, and total proteins for evaluation of diabetic status (12). Because questions have been raised about the capacity of these columns (13,14) , we investigated examined, only IgG shows more than 1 to 2% glycation in normal individuals.
By contrast, diabetics with sustained above-normal blood glucose concentrations show substantially more glycation. Furthermore, the differences in glycation among individual serum proteins are extreme. The differences appear to depend on susceptibility to glycation and biological half-life. The dominant factor at low to moderate glucose concentrations appears to be half-life, those proteins with longer half-lives showing greater glycation. This is consistent with previous kinetic studies with hemoglobin (14, 16). At high glucose concentrations, differences in the inherent glycatabiity of the proteins become more important; the basis for such differences is still poorly understood.
In Table 2 we compare the relative extents of in vivo and in vitro glycation for seven serum proteins with reported values for biological half4ife, lysine content, and carbohydrate content of each protein. As might be expected, there is, in general, a positive relation between protein half-life and extent of in vivo glycation. However, additional factors are clearly involved, because complement C3 shows twice as much glycation in vivo as fibrinogen, even though both proteins have similar half-lives and fibrinogen appears to be much more susceptible to in vitro glycation.
Non-enzymic
glycation is thought to involve primarily the epsilon amino groups of lysine residues as well as the primary amino groups of N-terminal amino acids (17) . However, Table 2 reveals little or no relation between mole percent lysine and in vitro or in vivo non-enzymic glycation. IgG, with only 7% lysine residues and unreactive N-terminal cyclic amino acids (18), is glycated much more readily than haptoglobin, which has more than 10% lysine residues.
Non-enzymatic glycation appears to show some degree of inverse relationship with carbohydrate content. Haptoglobin and alpha-1-antitrypsin, with about 12% carbohydrate, show little glycation; albumin and immunoglobulin G, with 0% and 3% carbohydrate, respectively, show relatively greater glycation.
One factor that appears to relate fairly well with extent of both in vivo and in vitro glycation is the overall acidity or basicity of the proteins. Agarose electrophoresis (Figures 2  and 4) clearly shows a descending gradient in percent glycation, from gamma globulins, which are the most basic and most heavily glycated, to the alpha-i globulins, which are the most acidic of the globulins and the least glycated. Albumin, which is still more acidic, however, is an exception to this principle, being quite glycated.
The clinical consequences of non-enzymic glycation ofserum proteins remain ambiguous. In non-diabetics the effects are probably negligible. In diabetic patients, however, extensively glycated species, such as immunoglobulins, complement, and fibrinogen, perhaps could exhibit significant alterations in function. Brownlee et al. (10) have shown that non-enzymic glycation of fibrinogen in vivo decreases the susceptibility of fibrin to degradation by plasmin. In vivo glycation also inhibits heparm-catalyzed human antithrombin ifi activity (9) . Furthermore, Dolhofer et al. (20) recently reported that the non-enzymic glycation of immunoglobulins in vitro resulted in loss of complement-fixing activity, although we have found that antigen binding by immunoglobulins is unaffected by in vitro glycation (21) . Whether such effects prove to be as important as the effects of glycation of long-lived proteins such as collagen and lens crystallins (22, 23) remains an open question.
